Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.44 |
| ▸ | CACNA2D2 | Q9NY47 | 4/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096794 | 0.88 | CYP1A2 (0.56) | KDM4EALDH1A1MAPTCYP1A2HPGD | |
| SCHEMBL6095421 | 0.88 | CYP1A2 (0.50) | KDM4EALDH1A1MAPTCYP1A2HPGD | |
| SCHEMBL6096068 | 0.85 | CYP1A2 (0.52) | KDM4EALDH1A1MAPTCYP1A2HPGD | |
| SCHEMBL6096823 | 0.85 | CYP1A2 (0.56) | KDM4EALDH1A1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL6098338 | 0.84 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2 | |
| SCHEMBL6097555 | 0.83 | CYP1A2 (0.72) | CYP1A2SMN1; SMN2 | |
| SCHEMBL6097502 | 0.82 | CYP1A2 (0.53) | KDM4EALDH1A1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL6097885 | 0.77 | CYP1A2 (0.56) | ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL6098897 | 0.76 | CYP1A2 (0.52) | KDM4EMAPTCYP1A2HPGDSMN1; SMN2 | |
| SCHEMBL14439485 | 0.76 | NPC1 (0.60) | KDM4EMAPTCYP1A2HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1495005-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | KDM4E 624/4885ALDH1A1 1304/4885MAPT 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.